Blood samples (10 mL) were drawn at the time of DEXA scans in postpartum period

Serum and plasma of samples were than seperated and stored at -80 ºC until the assay. Serum phosphorus (P) and calcium (Ca) were measured by Ion selective electrode (ISE) and alkaline phosphatase (ALP) activity was measured by kinetic enzymatic method, with reagents of Beckman Coulter, on an auto-analyser (Olympus AU5400, Beckman Coulter, Inc., U.S.A.). Serum intact parathormone (iPTH) was analyzed by two-site immunoenzymatic method and 25-hidroxy D levels were analyzed by competetive immunoenzymatic method on UniCel DxI 800 Immunoassay System (Beckman Coulter, Inc., U.S.A.).

Hyperemesis Gravidarum

DEXA

Hyperemesis Gravidarum and Osteoporosis

Is Hyperemesis Gravidarum a Risk Factor for Osteoporosis ?

All patients were performed on a standard dual energy x-ray absorptiometry (DEXA, Hologic Discovery Wi S/N 80848) during early postpartum period ( frequently in two days after birth before discharge of patients) by a single technician to assess osteoporosis. Blood samples include laboratory parameters associated with osteoporosis (Vitamin D, ALP, P, Ca and PTH).

Blood samples (10 mL) were drawn at the time of DEXA scans in postpartum period and collected into ethylenediaminetetraacetate (EDTA) containing sterile tubes and serum separator tubes (SSTs) to assess osteoporosis. Blood samples include laboratory parameters associated with osteoporosis (Vitamin D, ALP, P, Ca and PTH).

Gulsum Uysal

Medical doctor

Adana Numune Training and Research Hospital

The first group was formed of the patients diagnosed hyperemesis gravidarum with dehydration

The control group was formed of the patients who were healthy pregnant women admitted to the clinic just for routine examination without any symptoms

Hyperemesis; Gravidarum, With Dehydration

Kayseri Training and Research Hospital

Endothelial Dysfunction in Hyperemesis Gravidarum

Erdem Sahin

Principal Investigator

Kayseri Education and Research Hospital

Phase 1 (12 months): all patients treated with cinacalcet alone; Phase 2 (12 months): all patients treated with cinacalcet plus alendronate

Hyperparathyroidism, Primary

Osteoporosis

During Phase 1 (months 1-12): oral administration; 30 mg twice/day (dose to be increased if needed).

cinacalcet

During Phase 2 (months 13-24): oral administration; 70 mg once/week (in addition to cinacalcet 30 mg twice/day as during Phase 1).

hyperparathyroidism/vomiting

Hyperemesis Gravidarum and Osteoporosis

Endothelial Dysfunction in Hyperemesis Gravidarum

Efficacy of Cinacalcet in the Control of Primary Hyperparathyroidism

과학이 뒷받침하는 가장 완벽한 약초 데이터베이스